AR035877A1 - Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen - Google Patents
Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienenInfo
- Publication number
- AR035877A1 AR035877A1 ARP020101679A ARP020101679A AR035877A1 AR 035877 A1 AR035877 A1 AR 035877A1 AR P020101679 A ARP020101679 A AR P020101679A AR P020101679 A ARP020101679 A AR P020101679A AR 035877 A1 AR035877 A1 AR 035877A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- halogen
- polysubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de N-óxido-antranilamida de fórmula general (1) en donde A representa el grupo -N(R7)-; W es oxígeno, azufre, dos átomos de hidrógeno o el grupo -N(R8)-; Z es una unión, el grupo -N(R10)- ó =N-, alquilo C1-12 ramificado o no ramificado o el grupo -(CRaRb)m-(CRcRd)n-(CReRf)o-, donde m, n y o son 0-3, Ra, Rb, Rc, Rd, Re, Rf son, independientemente entre sí, hidrógeno, flúor, alquilo C1-4 o el grupo -N(R11)- y/o Ra y/o Rb con Rc y/o Rd o Rc con Re y/o Rf pueden formar una unión, o hasta dos de los radicales Ra-Rf pueden formar un puente, cada uno de ellos con hasta 3 átomos de C hacia R1 o hacia R7; X es alquilo C1-6; R1 es alquilo C1-12 o alquenilo C2-12 ramificado o no ramificado, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, ciano, alquiloxi C1-6, aralquiloxi, alquilo C1-6 y/o por el grupo NR12R13; o es cicloalquilo C3-10 o cicloalquenilo C3-10, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, ciano, alquiloxi C1-6, alquilo C1-6 y/o por el grupo NR12R13; o es arilo o hetarilo, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, ciano, cianoalquilo C1-6, alquiloxi C1-6, aralquiloxi, alquilo C1-6, haloalquilo C1-6 o por el grupo =O, -OR14 ó -R14; R2 es hetarilo no sustituido o en caso dado, mono- o polisustituido de modo igual o diferente por ciano, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, amino, hidroxi y/o por el grupo -OR18 ó -R19, que tiene por lo menos un grupo N-óxido; D es un átomo de nitrógeno o el grupo C-R3; E es un átomo de nitrógeno o un grupo C-R4; F es un átomo de nitrógeno o un grupo C-R5; G es un átomo de nitrógeno o un grupo C-R6, en donde R3, R4, R5 y R6 son hidrógeno, halógeno o alcoxi C1-6, alquilo C1-6 o carboxialquilo C1-6 no sustituido o en caso dado, mono- o polisustituido por halógeno; R7 es hidrógeno o alquilo C1-6 o forma un puente con Ra-Rf desde Z o hacia R1 con hasta 3 miembros de anillo; R8, R9, R10 y R11 son hidrógeno o alquilo C1-6; R12 y R13 son hidrógeno, alquilo C1-6 o forman un anillo que puede contener otro heteroátomo; R14 es el grupo (CH2-CH2-O)u(CH2)v-R15; R15 es arilo, hetarilo, alquilo C1-6, aralquilo, -CH2CN o el grupo NR16R17; R16 y R17 es hidrógeno, alquilo C1-6, acilo C1-6 o forman un anillo que puede contener otro heteroátomo; R18 es el grupo (CH2-CH2-O)w(CH2)p-R15; R19 es arilo, hetarilo, alquilo C1-6, aralquilo, -CH2CN o el grupo NR16R17 y u, v, w y p son 0-5, y sus isómeros y sales. Estos compuestos son identificados como inhibidores de la tirosinakinasa KDR y FLT, y son particularmente apropiados para el tratamiento de aquellas enfermedades que son originadas o estimuladas por la angiogénesis persistente provocada por el receptor VEGF o un aumento de la permeabilidad vascular. Los compuestos de fórmula (1) también presentan una excelente acción como inhibidores de la VEGFR-kinasa 3 y por ello son apropiados como inhibidores eficaces de la linfangiogénesis. Medicamentos que contienen al menos un compuesto de fórmula (1) y uso de estos compuestos para preparar un medicamento destinado al tratamiento de psoriasis, sarcoma de Kaposi, restenosis, endometriosis, mal de Crohn, enfermedad de Hodkin, leucemia, artritis tal como la artritis reumatoide, hemangioma, angiofibroma, enfermedades oculares tal como retinopatía diabética, el glaucoma neovascular, enfermedades renales tal como la glomerulonefritis, nefropatía diabética, nefroesclerosis maligna, síndromes microangiopáticos trómbicos, rechazos de transplantes y glomerulopatía, enfermedades fibróticas como cirrosis hepática, enfermedades proliferativas de células masangiales, ateroesclerosis, lesiones del tejido nervioso, inhibición de la reoclusión de vasos después de cateterismo con globo dilatable, a la colocación de prótesis vasculares o de dispositivos mecánicos para mantener abiertos los vasos como, por ejemplo, stents, a actuar como inmunosupresores y favorecer la curación de heridas sin dejar cicatriz, y a los casos de léntigo senil y dermatitis de contacto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001123573 DE10123573B4 (de) | 2001-05-08 | 2001-05-08 | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE2001125293 DE10125293A1 (de) | 2001-05-15 | 2001-05-15 | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035877A1 true AR035877A1 (es) | 2004-07-21 |
Family
ID=26009295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101679A AR035877A1 (es) | 2001-05-08 | 2002-05-08 | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen |
Country Status (6)
Country | Link |
---|---|
US (1) | US7459470B2 (es) |
EP (1) | EP1389201A1 (es) |
JP (1) | JP2004528378A (es) |
AR (1) | AR035877A1 (es) |
PE (1) | PE20021074A1 (es) |
WO (1) | WO2002090349A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
US8987262B2 (en) | 2007-10-19 | 2015-03-24 | Universite de Bordeaux | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
EP2050441A1 (en) * | 2007-10-19 | 2009-04-22 | Université Victor Segalen Bordeaux 2 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
KR20110045095A (ko) | 2008-08-27 | 2011-05-03 | 레오 파마 에이/에스 | Vegfr-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체 |
CN103827105B (zh) | 2011-08-18 | 2016-08-17 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物 |
CN103958511A (zh) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
-
2002
- 2002-05-03 EP EP02740563A patent/EP1389201A1/de not_active Withdrawn
- 2002-05-03 JP JP2002587429A patent/JP2004528378A/ja active Pending
- 2002-05-03 WO PCT/EP2002/004923 patent/WO2002090349A1/de active Application Filing
- 2002-05-03 US US10/476,755 patent/US7459470B2/en not_active Expired - Fee Related
- 2002-05-08 PE PE2002000385A patent/PE20021074A1/es not_active Application Discontinuation
- 2002-05-08 AR ARP020101679A patent/AR035877A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20050032816A1 (en) | 2005-02-10 |
WO2002090349A1 (de) | 2002-11-14 |
JP2004528378A (ja) | 2004-09-16 |
US7459470B2 (en) | 2008-12-02 |
EP1389201A1 (de) | 2004-02-18 |
PE20021074A1 (es) | 2003-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
AR035879A1 (es) | Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
CA2787121C (en) | Aminopyridine derivatives as anti-malarial agents | |
CN112601750A (zh) | 用于治疗癌症的作为ptpn11(shp2)抑制剂的6-(4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基)-3-(2,3-二氯苯基)-2-甲基嘧啶-4(3h)-酮衍生物及相关化合物 | |
AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
RU2017138972A (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
DE60032482D1 (de) | 5-cyano-2-aminopyrimidine derivate | |
AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
JP2014519518A5 (es) | ||
EA200800815A1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
PT1888584E (pt) | Compostos tricíclicos à base de 1,6-di-hidro-1,3,5,6- tetraaza-as-indaceno e composições farmacêuticas que os compreendem, enquanto inibidores da actividade da enzima ikk | |
MY141597A (en) | 2,4-disubstituted thiazolyl derivatives | |
AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
DE69926542D1 (de) | Aminopyrazol derivate | |
DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
EA023998B1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
WO2001064200A3 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
AU2009206775A1 (en) | Protein kinase inhibitors and use thereof | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |